相关实验视频

Updated: May 25, 2025

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

SGLT2 抑制剂的抗炎作用:专注于巨细胞

Elena Y Rykova¹, Vadim V Klimontov^1,2, Elena Shmakova^1,3

¹Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (IC&G SB RAS), Lavrentjev Prospect 10, 630090 Novosibirsk, Russia.

International journal of molecular sciences

|February 26, 2025

概括

-葡萄糖共传输体2 (SGLT2) 抑制剂通过向巨细胞来减少炎症,巨细胞在代谢炎症中至关重要. 这些药物在糖尿病,脏疾病和心力衰竭中具有保护作用.

科学领域:

药理学药理学是指药理学的学科.
免疫学免疫学免疫学
代谢疾病代谢疾病

背景情况:

由于SGLT2抑制剂在糖尿病,慢性病和心力衰竭中的保护作用,人们越来越认识到它们的非血糖作用.
SGLT2 抑制剂的抗炎功能是最近研究的一个重要领域.
巨细胞是代谢炎症的核心参与者,使它们成为理解SGLT2抑制剂作用的关键焦点.

研究的目的:

审查关于SGLT2抑制剂抗炎活性的临床和实验证据.
专门研究SGLT2抑制剂对巨细胞的影响.
阐明这些抗炎作用背后的分子机制.

主要方法:

对2型糖尿病患者的临床研究的综述.
对糖尿病和非糖尿病动物模型实验研究的分析.
研究涉及巨细胞功能中的分子通路.

主要成果:

SGLT2 抑制剂可以降低2型糖尿病患者的炎症媒介.
在动物模型中,SGLT2抑制剂抑制巨细胞炎症激活,单细胞招募和M1极化.
分子机制包括炎症酶减弱,TLR4/NF-κB通路抑制,AMPK,PI3K/Akt,ERK和JAK/STAT通路的调节.

结论:

SGLT2 抑制剂具有显著的抗炎性质,特别是通过它们对巨细胞的作用.
这些发现支持SGLT2抑制剂超出血糖控制的治疗潜力.
需要进一步的研究才能充分理解所涉及的分子,细胞和生理机制.

关键词:

慢性脏疾病慢性脏疾病糖尿病糖尿病患者糖尿病患者心脏衰竭是因为心脏衰竭.这是一种炎症炎症炎症炎症.巨细胞是什么?巨细胞是什么?信号通道的信号通道.糖共传输体 2 抑制剂

更多相关视频

Depletion and Reconstitution of Macrophages in Mice

Depletion and Reconstitution of Macrophages in Mice

Published on: August 1, 2012

Investigation of Macrophage Polarization Using Bone Marrow Derived Macrophages

Investigation of Macrophage Polarization Using Bone Marrow Derived Macrophages

Published on: June 23, 2013

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucose Transporters

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...